Personalizing Immune Checkpoint Inhibitor Therapy

Withdrawn before enrolling

Conditions studied: Lung Cancer Stage IV

In brief

This prospective, observational study will evaluate whether vitro testing of tumor tissue and white blood cells from patients with lung cancer who are being treated with immune checkpoint inhibitors and other standard of care approaches, predicts clinical response to these agents.

Key facts

Study ID

NCT03409341

Run by

Holy Cross Hospital, Maryland

People needed

0

Starts

2019-02-01

Expected to finish

2020-09-22

Last updated by the study team

2020-09-24

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with lung cancer about to undergo diagnostic/excisional biopsy with the intent to receive therapy with immune checkpoint inhibitors
• Availability of fresh tumor tissue removed at excisional biopsy or diagnostic biopsy
• Informed consent

You may not qualify if…

• Lack of informed consent

Where it is running

• Holy Cross Hospital — Silver Spring, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.